By SPC News Staff
The FDA granted accelerated approval to durvalumab (Imfinzi, AstraZeneca/MedImmune) to treat patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy.
MAY 3, 2017